Statins Are Associated with Improved Survival of Patients with Gastric Cancer: A Systematic Review and Meta-Analysis

Statins are associated with gastric cancer (GC) risk. The present study aimed to clarify the efficacy of statins on the overall survival (OS) benefits in patients with GC. Publications were retrieved from PubMed, Embase, and the Cochrane Library as of April 2022. Data from the eligible cohort, case-...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical practice (Esher) 2022, Vol.2022, p.4938539-9
Main Authors: Yuan, Mingjie, Han, Shuyi, Jia, Yanfei, Feng, Jiankai, Liu, Duanrui, Su, Zhenguo, Liu, Xiangdong
Format: Article
Language:English
Subjects:
Adjuvants
Apoptosis
Cancer therapies
Chemotherapy
Clinical trials
Cohort analysis
Gastric cancer
Gastrointestinal surgery
Liver cancer
Medical prognosis
Meta-analysis
Mortality
Patients
Prescriptions
Radiation therapy
Review
Statins
Statistical analysis
Survival
Systematic review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Statins are associated with gastric cancer (GC) risk. The present study aimed to clarify the efficacy of statins on the overall survival (OS) benefits in patients with GC. Publications were retrieved from PubMed, Embase, and the Cochrane Library as of April 2022. Data from the eligible cohort, case-control studies, and randomized control trials (RCTs) were extracted for the meta-analysis. Hazard ratio (HR) and 95% confidence intervals (CI) were used to assess the association between statins users and OS in GC patients. Subgroup analysis was performed based on the study design (prospective vs. retrospective). A total of 6 studies encompassing 5693 GC patients were included. Statins added to the standard treatment prolonged the patient’s OS outcome (HR (95% CI): 0.72 (0.53–0.97), p = 0.032; I2 = 88.0%, pheterogeneity 
ISSN:1368-5031
1742-1241
DOI:10.1155/2022/4938539